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Abstract
The morphological type of tumor is a crucial factor in selecting the type and volume of surgery.
The objective of the research was to determine the effect of tumor histological type on survival rates in patients with locally
advanced stomach cancer after combined surgery.
Materials and methods. The study included 990 patients; there were 714 men and 276 women. All patients underwent
combined surgery: distal subtotal gastric resection was performed in 222 cases; proximal subtotal gastric resection was used
in 129 cases; gastrectomy was applied in 639 cases. Statistical analysis of the obtained data was performed using the SPSS
13.0 software program. The results were considered statistically significant at p<0.05.
Results. The study of certain morphological types of tumor depending on the patients’ age and sex, as well as clinical and
morphological features revealed a significant predominance of adenocarcinoma (77.1%) over other types and a significantly
smaller number of undifferentiated tumors – 20.6%; squamous cell cancer and small-cell cancer constituted 1.3% and 1.0%,
respectively. The average life expectancy after surgery was 37.51±2.69 months (p=0.021); in women, it was slightly higher
compared to men – 43.75±5.70 months vs. 35.13±3.02 months (p=0.057). The overall 5-year survival rate for all patients
was 17.32±1.49%; for men – 16.11±1.72% (p=0.005), for women – 20.46±2.99% (p=0.399); however, these differences
were not statistically significant (p=0.087).
Conclusions. After surgery, there were no significant differences in the average life expectancy of patients with the same
histological forms of gastric adenocarcinoma between men and women (p>0.05), while significant differences were observed
between patients (both men and women) with adenocarcinoma and undifferentiated adenogenic stomach cancer (p<0.05).
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Problem statement and analysis of the
recent research
Despite advances in early cancer detection, stomach cancer
(SC) remains the leading cause of cancer death after lung
cancer worldwide [4]. It is mainly due to the fact that a
significant proportion of locally advanced forms of SC is
diagnosed too late, especially in Ukraine (over 20-25%) [1].
Surgery which involves achieving a R0 resection, is often
used in patients with locally advanced forms (T4) of SC [8].
Over recent years, the increase in the rate of complications
in the postoperative period as well as survival rate has been
actively discussed. Some researchers have reported minor
changes in the survival of patients who underwent combined
surgery [6]. However, significantly higher rates of compli-
cations and mortality as well as a slightly longer duration
of in-patient treatment due to extended resections have been
indicated by other authors [6].
The microscopic type of tumor is a crucial factor in se-
lecting the type and volume of surgery [7]. In addition, other
clinical and pathological characteristics of tumor such as the
depth of invasion, lymph node status, macroscopic type, tu-
mor size and others affect the prognosis of locally advanced
SC.
The objective of the research was to study the effect of his-
tological type of tumor on survival and prognosis of patients
with locally advanced SC after combined surgery.
1. Materials and methods
The study included 990 patients; there were 714 men and 276
women. All patients underwent various types of combined
surgery for SC in Lviv Regional Clinical Oncology Center.
Surgery was considered “combined” when the main type of
surgery (subtotal gastric resection or gastrectomy) was com-
bined with en bloc resection or removal of other (related)
organs (the mesentery of the transverse colon, the transverse
colon, the body and tail of the pancreas, spleen, diaphragm,
soft tissue of the anterior abdominal wall). Distal subtotal
gastric resection (n=222), proximal subtotal gastric resection
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(n=129) or gastrectomy (n=639) were performed depending
on the location of the primary lesion and other JGCA criteria
[5]. The additional organ resection was performed to achieve
R0 resection; in some cases, due to iatrogenic damage to the
organ. All the data were statistically processed using the SPSS
13.0 software program (Chicago, IL). The obtained numer-
ical indicators were presented as M±m, and the difference
between groups was compared using the independent bilateral
T-test. To compare frequency parameters between groups,
the χ2-square test (Fisher’s exact test) was used. The time
interval between the time of surgery and the date of death
or last contact (if alive) was used to analyze survival data by
means of the Kaplan-Meier method and the log-rank test. In
all cases, the results were considered statistically significant
at p<0.05
2. Results
The average age of patients was 60.02±0.30 years (generally
from 21 up to 87 years); male patients prevailed over female
patients– men:women = 2.6:1.0 (72.1%: 27.9%). Among all
combined surgical procedures, combined gastrectomy pre-
dominated over combined subtotal gastric resection and prox-
imal gastric resection - 5:2.9:1.
The average life expectancy of 701 (512 men, 189 women)
patients after surgery was 37.51±2.69 months (p=0.021); in
women, it was slightly higher compared to men – 43.75±5.70
months vs. 35.13±3.02 months (p=0.057). The median sur-
vival time was 12.03±0.59 months, 20.46±2.99 months and
16.11±1.72 months, respectively (Table 1). The highest av-
erage life expectancy was in patients with adenocarcinoma –
41.21±3.29 months; the lowest average life expectancy was
in patients with squamous cell cancer – 10.79±4.73 months
(p=0.041); significantly lower average life expectancy was ob-
served in patients with undifferentiated cancer – 25.29±3.28
months (p=0.015). The study of certain morphological types
of tumors depending on the patients’ age and sex, as well as
clinical and morphological features revealed a significant pre-
dominance of adenocarcinoma (77.1%) over other types and
a significantly smaller number of undifferentiated tumors –
20.6%; squamous cell cancer and small-cell cancer constituted
1.3% and 1.0%, respectively (Table 2).
3. Discussion
There were some differences in the average life expectancy
by neoplasm morphology; the highest average life expectancy
was observed in patients with adenocarcinoma of the stom-
ach – 41.213±3.291 months, and the lowest one was ob-
served in patients with squamous cell cancer – 10.793±4.734
months. There were detected significant differences in life
expectancy between these groups of patients (p=0.041) and pa-
tients with adenocarcinoma as well as undifferentiated cancer
(25.298±3.281 months) – p=0.015. There were no significant
sex differences within the same type of morphology (p>0.05)
[3]. The differences between life expectancy of patients with
adenocarcinoma and small-cell cancer (29.34±28.97 months)
were insignificant– p=0.491. In both male and female patients,
the same patterns were mostly observed; it was apparently
due to small number of observations – the differences were
not determined between patients with small-cell cancer and
squamous cell cancer; however, there was a significant differ-
ence between patients with adenocarcinoma and undifferen-
tiated cancer (p=0.011). It should be noted that within each
individual morphological form, there were observed minor
gender differences; however, all of them were not statisti-
cally significant (p>0.05) [6, 8, 9]. There were determined
no statistically significant differences in the average age of
patients with different morphological types (p>0.1) [2]. De-
spite the overwhelming number of male patients (p<0.01),
the most significant differences in adenocarcinomas and un-
differentiated cancer were identified in both men and women
(p<0.01) (Table 2), in rest cases there were not significant dif-
ferences between the proportions of men and women (p>0.05)
[6]. The most marked differences in the relative number of
exophytic and endophytic tumors were found between ade-
nocarcinoma and undifferentiated cancer (p<0.01) as well
as endophytic tumors – between adenocarcinoma and small-
cell cancer (p<0.05). There was no significant difference
in the number of exophytic and endophytic tumors between
the macroscopic forms of adenocarcinoma (p>0.1); however,
the number of mesophytic tumors was significantly smaller
compared to the previous one (p<0.01). Such value was not
typical for other morphological types of tumors; however,
undifferentiated tumors had significantly more endophytic
forms (p<0.01) [8]. The predominant depth of invasion was
T4 (p<0.01).
The status of affected lymph nodes in patients with adeno-
carcinoma corresponded with category N0 and N1 (p<0.01);
similar tendency was typical for patients with undifferentiated
cancer (p<0.01); for other morphological types these ratios
were not significant (p >0.05) [6, 8].
In patients with adenocarcinoma, combined gastrectomy
predominated over combined subtotal and proximal resec-
tion 4:2.5:1 (p<0.01); the same tendency was determined for
other morphological types; the most expressed tendency was
observed in patients with undifferentiated cancer – 6:5:1 [10].
The overall 5-year survival rate for all patients was 17.32±
1.49%; for men – 16.11±1.72% (p=0.005), for women –
20.46±2.99% (p=0.399) (Table 1, Fig. 1); however, these
differences were not statistically significant (p=0.087). As
for the difference in the 5-year survival rate by morphology,
the difference was significant between male patients with ade-
nocarcinoma and undifferentiated cancer (17.52±2.05% and
12.53±3.27%, respectively p=0.041 [3]; in other cases, the
5-year survival was not achieved (Table 1, Fig. 2). In female
patients, the highest 5-year survival was observed in patents
with adenocarcinoma 24.69±3.96% (Table 1, Fig. 3), in pa-
tients with undifferentiated cancer – 11.47±4.06, there was
no significant difference between them (p=0.502); in other
cases, the 5-year survival rate was not reached.
Features of Histological Forms of Tumor Growth in Patients Who Underwent Combined Surgery for Stomach Cancer
— 3/5
Table 1. Average life expectancy of patients with stomach cancer depending on histological forms of tumor growth and gender
#
Histological Average life expectancy (months) Median of average 5-year
forms M ±m 95% confidence interval life expectancy (months) survival rate (%)(WHO) Lower limit Upper limit M ±m M ±m
All patients
1 Adenocarcinoma 41.21 3.29 34.76 47.66 12.85 0.88 19.33 1.83
2 Small-cell cancer 29.34 28.97 0.00 86.13 0.39 0.05 33.33 27.22
3 Undifferentiated cancer 25.29 3.28 18.87 31.73 9.73 1.26 12.04 2.55
4 Squamous cell cancer 10.79 4.73 1.51 20.07 5.29 1.74 - -
Total 37.51 2.69 32.24 42.78 12.03 0.69 17.32 1.49
Men
5 Adenocarcinoma 37.99 3.59 30.95 45.04 12.03 0.84 17.52 2.05
6 Small-cell cancer 0.36 0.03 0.29 0.43 0.33 - - -
7 Undifferentiated cancer 24.74 4.03 16.85 32.62 8.45 0.98 12.53 3.27
8 Squamous cell cancer 6.57 2.48 1.72 11.42 5.29 2.37 - -
Total 35.13 3.02 29.21 41.05 11.28 0.77 16.113 1.72
Women
9 Adenocarcinoma 50.45 7.48 35.786 65.11 14.69 1.76 24.69 3.96
10 Small-cell cancer 87.29 0.00 87.29 87.29 87.29 - 1.00 0.01
11 Undifferentiated cancer 26.33 5.46 15.62 37.04 12.13 1.66 11.47 4.06
12 Squamous cell cancer 40.34 0.00 40.34 40.34 40.34 - - -
Total 43.75 5.70 32.58 54.93 14.17 1.43 20.46 2.99
Figure 1. Comparison of the distribution functions of
survival by the histological type in patients who underwent
combined surgery.
Figure 2. Comparison of the distribution functions of
survival by the histological type in male patients who
underwent combined surgery.
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Table 2. Clinical and morphological data of patients with different histological types of stomach cancer
Adenocarcinoma1 (n=763) Small-cell cancer2 (n=10) Undifferentiated cancer3 (n=204) Squamous cell cancer4 (n=13) p-value
Age, years 60.58±0.34 55.20±2.12 58.84±0.92 59.00±3.01
p1-2=0.793
p1-3=0.363
p1-4=0.653
Sex
Women 197 (25.8%) 4 (40.0%) 74 (36.3%) 1 (7.7%)
p1-2>0.05
p1-3<0.01
p1-4>0.05
Men 566 (74.2%) 6 (60.0%) 130 (63.7%) 12 (92.3%)
p1-2>0.05
p1-3<0.01
p1-4>0.05
Macroscopic type
Exophytic 272 (35.6%) 2(20.0%) 28 (13.7%) 5 (38.5%)
p1-2>0.05
p1-3<0.01
p1-4>0.05
Endophytic 224 (29.4%) 8 (80.0%) 90 (44.1%) 3 (23.1%)
p1-2 <0.05
p1-3<0.01
p1-4>0.05
Mesophytic 132 (17.3%) - 32 (15.7%) 3 (23.1%) p
1-3>0.05
p1-4>0.05
Cancer originating from gastric ulcer 9 (1.2%) - 1 (0.5%) - -
Tumor localization
Proximal 381 (49.9%) 3 (30.0%) 73 (35.8%) 12 (92.3%)
p1-2>0.05
p1-3<0.01
p1-4<0.01
Body 147 (19.3%) 1 (10.0%) 69 (33.8%) 1 (7.7%)
p1-2>0.05
p1-3<0.01
p1-4>0.05
Distal 185 (24.2%) 4 (40.0%) 33 (16.2%) - p
1-2>0.05
p1-3<0.05
Subtotal and 47 (6.2%) 2 (20.05) 28 (13.7%) - p
1-2>0.05
total involvement p1-3<0.01
Multiple involvement 3 (0.3%) - 1 (0.5%) -
Depth of invasion
T1 10 (1.3%) -
T2 35 (4.6%) - 14 (6.9%) 1 (7.7%) p
1-3>0.05
p1-4>0.05
T3 292 (38.3%) 1 (10.0%) 90 (44.1%) 7 (53.8%)
p1-2>0.05
p1-3>0.05
p1-4>0.05
T4 415 (54.4%) 9 (90.0%) 100 (49.0%) 5 (38.5%)
p1-2>0.05
p1-3>0.05
p1-4>0.05
Regional lymph nodes
N0 314 (41.2%) 5 (50.0%) 67 (32.8%) 3 (23.1%)
p1-2>0.05
p1-3<0.05
p1-4>0.05
N1 301 (39.4%) 2 (20.0%) 92 (45.1%) 7 (53.8%)
p1-2>0.05
p1-3<0.05
p1-4>0.05
N2 97 (10.1%) 2 (20.0%) 36 (17.6%) 3 (23.1%)
p1-2>0.05
p1-3>0.05
p1-4>0.05
N3 3 (0.4%) - 3 (1.5%) -
Type of surgery
Gastrectomy 463 (60.7%) 6 (60.0%) 161 (78.9%) 9 (69.2%)
p1-2>0.05
p1-3 <0.01
p1-4>0.05
Distal subtotal 185 (24.2%) 4 (40.0%) 33 (16.2%) - p
1-2>0.05
gastric resection p1-3 <0.05
Proximal subtotal 115 (15.1%) - 10 (4.9%) 4 (30.8%) p
1-3 <0.01
gastric resection p1-4>0.05
4. Conclusions
After surgery, there were no significant differences in the
average life expectancy of patients with the same histologi-
cal forms of SC between men and women (p>0.05), while
significant differences were observed between patients (both
men and women) with adenocarcinoma and undifferentiated
adenogenic stomach cancer (p<0.05).
Taking into account the fact that combined surgery for SC
is used mainly in older male patients, it should be considered
in view of the current trend to the increase in the volume
of surgery as well as the expansion of the indications for its
performance.
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Figure 3. Comparison of the distribution function of
survival by the histological type in female patients who
underwent combined surgery.
5. Prospects for further research
Further researche should be directed to ascertain the survival
of patients with locally advanced SC depending on the HER2
receptor expression of primary tumors.
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